<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68906">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019940</url>
  </required_header>
  <id_info>
    <org_study_id>1308012549</org_study_id>
    <nct_id>NCT02019940</nct_id>
  </id_info>
  <brief_title>A Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>Structural and Spectroscopy Pharmaco-Imaging Paradigm to Investigate the Effect of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for PTSD</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, parallel group study will evaluate the
      safety and efficacy of riluzole in patients with PTSD. Patients will be randomized to
      receive either riluzole 50mg twice per day or placebo orally for 8 weeks as outpatient, with
      a 4-week open-label period.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale (CAPS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Traumatic Stress Disorder Checklist (PCL)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole 50 mg orally twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PTSD participants

        Inclusion Criteria:

          -  Male or female subjects between the ages of 18-50 years;

          -  Able to provide written informed consent;

          -  Current Post Traumatic Stress Disorder;

          -  Clinician Administered PTSD Scale for DSM-IV-TR (CAPS) score of 50 or higher;

          -  Be able to understand and speak English;

        Exclusion Criteria:

          -  Breastfeeding women and pregnant women, or women of child bearing potential who are
             not using a medically accepted means of contraception;

          -  Any history indicating learning disability, mental retardation, or attention deficit
             disorder;

          -  Serious suicide or homicide risk;

          -  Unstable medical illness;

          -  Substance use disorders active within the last three months, bipolar disorder
             (current or past), psychotic disorder (current or past);

          -  History of a seizure disorder or clinical evidence of untreated hypothyroidism;

          -  Patients requiring excluded medications

          -  Psychotic features in the current episode or a history of psychotic features;

          -  Patients with a history of antidepressant-induced hypomania;

          -  Patients with any evidence of clinically significant liver abnormalities, or any
             liver transaminase level &gt; 1.5 x ULN at initial screening, or &gt; 5 x ULN during
             treatment;

          -  Axis II personality disorders that are the primary purpose of treatment, or would
             interfere with a patient's safety or compliance;

          -  Patients currently being treated for a respiratory disorder (including asthma or
             COPD);

          -  Structured psychotherapy focused on treatment of PTSD is exclusionary unless the
             subject has had at least 8 weeks of treatment prior to randomization;

        Healthy Participants

        Inclusion Criteria:

          -  Male or female between the ages of 18-50 years;

          -  Able to provide written informed consent;

          -  Be able to understand and speak English.

        Exclusion Criteria:

          -  Breastfeeding women and pregnant women, or women of child bearing potential who are
             not using a medically accepted means of contraception;

          -  Any lifetime history of DSM-IV-TR mood, anxiety, psychotic or personality disorders
             confirmed after comprehensive psychiatric evaluation;

          -  Any history of serious medical or neurological illness;

          -  Unstable medical illness;

          -  Substance or alcohol dependence or abuse active within the last three months;

          -  Any history indicating learning disability, mental retardation, or attention deficit
             disorder;

          -  History of significant head injury or other trauma resulting in a loss of
             consciousness for 30 minutes or more;

          -  History of a seizure disorder or clinical evidence of untreated hypothyroidism;

          -  Subjects currently being treated for a respiratory disorder (including asthma or
             COPD);

          -  History of claustrophobia as determined by open-ended psychiatric interview;

          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal
             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening
             questionnaire.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadi Abdallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for PTSD / Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Douglas-Palumberi, M.A.</last_name>
    <phone>203 932 5711</phone>
    <phone_ext>5314</phone_ext>
    <email>heather.douglas-palumberi@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Neuroscience Division, National Center for PTSD</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Douglas-Palumbri, MA</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>5314</phone_ext>
      <email>heather.douglas-palumberi@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Chadi Abdallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ptsd.va.gov/</url>
    <description>National Center for PTSD</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Chadi Abdallah</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
